Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease

Yi Hong Zhang, James Raymick, Sumit Sarkar, Debomoy Lahiri, Balmiki Ray, David Holtzman, Melanie Dumas, Larry C. Schmued

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Alzheimer's disease (AD), the most common human neurodegenerative disease, is characterized pathologically by numerous deposits of amyloid plaques in the brain. Systemic administration of clioquinol (CQ) and inoculation with amyloid-beta42 (Aβ342) vaccines have been demonstrated to significantly inhibit deposits of amyloid in AD brains. However, each of these treatments has also been reported to be neurotoxic. The generation of transgenic mice models of AD has made it possible to study aspects of this disease employing experimental animals. In the present study, we investigated the efficacy and toxicity of CQ and A(342 vaccine in a transgenic AD (APP/PS1) mouse model. Our results confirmed that both CQ and A(342 vaccine were effective in significantly reducing the deposits of amyloid in the brains of transgenic AD mice. We also report here that systemic CQ induces myelinopathies in the dorsal lateral geniculate nucleus (DLG), which was almost devoid of amyloid plaques and is the primary site of retinal efferent projections via the optic nerve. This is the first report that systemic administration of CQ causes myelinopathies in the central nervous system (CNS) of a transgenic AD mouse model as well as wild-type mice. Inoculation with an Aβ42 vaccine was also found, for the first time, to result in a significant increase in plaque-independent astrocytic hyperplasia in the dorsal part of the lateral septal nucleus (LSD) which was also devoid of plaques, reflecting potential brain inflammatory processes.

Original languageEnglish
Pages (from-to)494-506
Number of pages13
JournalCurrent Alzheimer Research
Volume10
Issue number5
DOIs
StatePublished - 2013

Fingerprint

Clioquinol
Alzheimer Disease
Amyloid Plaques
Vaccines
Brain
Geniculate Bodies
Lysergic Acid Diethylamide
Septal Nuclei
Optic Nerve
Amyloid
Neurodegenerative Diseases
Transgenic Mice
Hyperplasia
Central Nervous System

Keywords

  • Alzheimer's disease
  • Amyloid plaque
  • Amyloid-beta
  • Astrocytes
  • Clioquinol
  • Myelinopathy
  • Transgenic mice
  • Vaccine

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease. / Zhang, Yi Hong; Raymick, James; Sarkar, Sumit; Lahiri, Debomoy; Ray, Balmiki; Holtzman, David; Dumas, Melanie; Schmued, Larry C.

In: Current Alzheimer Research, Vol. 10, No. 5, 2013, p. 494-506.

Research output: Contribution to journalArticle

Zhang, Yi Hong ; Raymick, James ; Sarkar, Sumit ; Lahiri, Debomoy ; Ray, Balmiki ; Holtzman, David ; Dumas, Melanie ; Schmued, Larry C. / Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease. In: Current Alzheimer Research. 2013 ; Vol. 10, No. 5. pp. 494-506.
@article{ea68949a4a074bc5b086e1ea9ad7e4e1,
title = "Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease",
abstract = "Alzheimer's disease (AD), the most common human neurodegenerative disease, is characterized pathologically by numerous deposits of amyloid plaques in the brain. Systemic administration of clioquinol (CQ) and inoculation with amyloid-beta42 (Aβ342) vaccines have been demonstrated to significantly inhibit deposits of amyloid in AD brains. However, each of these treatments has also been reported to be neurotoxic. The generation of transgenic mice models of AD has made it possible to study aspects of this disease employing experimental animals. In the present study, we investigated the efficacy and toxicity of CQ and A(342 vaccine in a transgenic AD (APP/PS1) mouse model. Our results confirmed that both CQ and A(342 vaccine were effective in significantly reducing the deposits of amyloid in the brains of transgenic AD mice. We also report here that systemic CQ induces myelinopathies in the dorsal lateral geniculate nucleus (DLG), which was almost devoid of amyloid plaques and is the primary site of retinal efferent projections via the optic nerve. This is the first report that systemic administration of CQ causes myelinopathies in the central nervous system (CNS) of a transgenic AD mouse model as well as wild-type mice. Inoculation with an Aβ42 vaccine was also found, for the first time, to result in a significant increase in plaque-independent astrocytic hyperplasia in the dorsal part of the lateral septal nucleus (LSD) which was also devoid of plaques, reflecting potential brain inflammatory processes.",
keywords = "Alzheimer's disease, Amyloid plaque, Amyloid-beta, Astrocytes, Clioquinol, Myelinopathy, Transgenic mice, Vaccine",
author = "Zhang, {Yi Hong} and James Raymick and Sumit Sarkar and Debomoy Lahiri and Balmiki Ray and David Holtzman and Melanie Dumas and Schmued, {Larry C.}",
year = "2013",
doi = "10.2174/1567205011310050005",
language = "English",
volume = "10",
pages = "494--506",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease

AU - Zhang, Yi Hong

AU - Raymick, James

AU - Sarkar, Sumit

AU - Lahiri, Debomoy

AU - Ray, Balmiki

AU - Holtzman, David

AU - Dumas, Melanie

AU - Schmued, Larry C.

PY - 2013

Y1 - 2013

N2 - Alzheimer's disease (AD), the most common human neurodegenerative disease, is characterized pathologically by numerous deposits of amyloid plaques in the brain. Systemic administration of clioquinol (CQ) and inoculation with amyloid-beta42 (Aβ342) vaccines have been demonstrated to significantly inhibit deposits of amyloid in AD brains. However, each of these treatments has also been reported to be neurotoxic. The generation of transgenic mice models of AD has made it possible to study aspects of this disease employing experimental animals. In the present study, we investigated the efficacy and toxicity of CQ and A(342 vaccine in a transgenic AD (APP/PS1) mouse model. Our results confirmed that both CQ and A(342 vaccine were effective in significantly reducing the deposits of amyloid in the brains of transgenic AD mice. We also report here that systemic CQ induces myelinopathies in the dorsal lateral geniculate nucleus (DLG), which was almost devoid of amyloid plaques and is the primary site of retinal efferent projections via the optic nerve. This is the first report that systemic administration of CQ causes myelinopathies in the central nervous system (CNS) of a transgenic AD mouse model as well as wild-type mice. Inoculation with an Aβ42 vaccine was also found, for the first time, to result in a significant increase in plaque-independent astrocytic hyperplasia in the dorsal part of the lateral septal nucleus (LSD) which was also devoid of plaques, reflecting potential brain inflammatory processes.

AB - Alzheimer's disease (AD), the most common human neurodegenerative disease, is characterized pathologically by numerous deposits of amyloid plaques in the brain. Systemic administration of clioquinol (CQ) and inoculation with amyloid-beta42 (Aβ342) vaccines have been demonstrated to significantly inhibit deposits of amyloid in AD brains. However, each of these treatments has also been reported to be neurotoxic. The generation of transgenic mice models of AD has made it possible to study aspects of this disease employing experimental animals. In the present study, we investigated the efficacy and toxicity of CQ and A(342 vaccine in a transgenic AD (APP/PS1) mouse model. Our results confirmed that both CQ and A(342 vaccine were effective in significantly reducing the deposits of amyloid in the brains of transgenic AD mice. We also report here that systemic CQ induces myelinopathies in the dorsal lateral geniculate nucleus (DLG), which was almost devoid of amyloid plaques and is the primary site of retinal efferent projections via the optic nerve. This is the first report that systemic administration of CQ causes myelinopathies in the central nervous system (CNS) of a transgenic AD mouse model as well as wild-type mice. Inoculation with an Aβ42 vaccine was also found, for the first time, to result in a significant increase in plaque-independent astrocytic hyperplasia in the dorsal part of the lateral septal nucleus (LSD) which was also devoid of plaques, reflecting potential brain inflammatory processes.

KW - Alzheimer's disease

KW - Amyloid plaque

KW - Amyloid-beta

KW - Astrocytes

KW - Clioquinol

KW - Myelinopathy

KW - Transgenic mice

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84885900082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885900082&partnerID=8YFLogxK

U2 - 10.2174/1567205011310050005

DO - 10.2174/1567205011310050005

M3 - Article

VL - 10

SP - 494

EP - 506

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 5

ER -